Advanced search    

Search: authors:"James A Karlowsky"

60 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

In Vitro Activities of Ceftobiprole and Doripenem Tested against Frequently Encountered Aerobic and Facultative Gram-Positive and Gram-Negative Bacterial Pathogens Isolated from Patients in Canadian Hospitals in 2007

BACKGROUND: In 2008, ceftobiprole was approved by Health Canada for the treatment of patients with complicated skin and skin structure infections including diabetic foot infections; approval of ceftobiprole by the United States Food and Drug Administration is pending. Doripenem is currently under review by Health Canada and was approved by the United States Food and Drug...

The New Fluoroquinolones: A Critical Review

OBJECTIVE: This paper reviews the literature available on the new fluoroquinolones – clinafloxacin, gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, sparfloxacin and trovafloxacin – to compare these agents with each other and contrast them with ciprofloxacin, an older fluoroquinolone.

Characterization of Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals: Results of the CANWARD 2007 Study

MSc Michael R Mulvey James A Karlowsky Daryl J Hoban George G Zhanel 54A Antimicrobial resistance; Multidrug-resistant; Pseudomonas aeruginosa - INtRoDuCtIoN: Pseudomonas aeruginosa is an important

Low Prevalence of VRE Gastrointestinal Colonization of Hospitalized Patients in Manitoba Tertiary Care and Community Hospitals

OBJECTIVE: To determine the prevalence of vancomycin-resistant enterococci (VRE) bowel colonization in hospitalized patients in Manitoba who had stool specimens collected for Clostridium difficile toxin and/or culture testing.

Low Prevalence of VRE Gastrointestinal Colonization of Hospitalized Patients in Manitoba Tertiary Care and Community Hospitals

OBJECTIVE: To determine the prevalence of vancomycin-resistant enterococci (VRE) bowel colonization in hospitalized patients in Manitoba who had stool specimens collected for Clostridium difficile toxin and/or culture testing.

Fidaxomicin: A Novel Agent for the Treatment of Clostridium difficile Infection

Clostridium difficile infection George G Zhanel Andrew J Walkty James A Karlowsky Clostridium difficile; Fidaxomicin; Infection; Recurrence; Treatment - BACkGROUND: Due to the limitations of existing

Fidaxomicin: A Novel Agent for the Treatment of Clostridium difficile Infection

Clostridium difficile infection George G Zhanel Andrew J Walkty James A Karlowsky Clostridium difficile; Fidaxomicin; Infection; Recurrence; Treatment - BACkGROUND: Due to the limitations of existing

Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada

Fosfomycin is a bactericidal agent that inhibits cell wall synthesis using a mechanism of action distinct from β-lactams or other antimicrobial agents. It is a broad-spectrum agent that is frequently active against antimicrobial-resistant bacterial pathogens including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), multidrug-resistant...

Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada

Fosfomycin is a bactericidal agent that inhibits cell wall synthesis using a mechanism of action distinct from β-lactams or other antimicrobial agents. It is a broad-spectrum agent that is frequently active against antimicrobial-resistant bacterial pathogens including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), multidrug-resistant...

Caulobacter Species as a Cause of Postneurosurgical Bacterial Meningitis in a Pediatric Patient

Kim Nichol MSc 0 James A Karlowsky 0 0 N Bridger, A Walkty, M Crockett, S Fanella, K Nichol, JA Karlowsky. Caulobacter species as a cause of postneurosurgical bacterial meningitis in a pediatric patient

Mutant Prevention Concentrations of Doripenem and Meropenem Alone and in Combination with Colistin (Polymyxin E), Levofloxacin and Tobramycin in Pseudomonas aeruginosa

Ed Tam Daryl J Hoban James A Karlowsky Doripenem; Meropenem; Mutant prevention; P aeruginosa - BACKGROUND: With a limited number of available antimicrobial agents to treat Pseudomonas aeruginosa

Mutant Prevention Concentrations of Doripenem and Meropenem Alone and in Combination with Colistin (Polymyxin E), Levofloxacin and Tobramycin in Pseudomonas aeruginosa

Ed Tam Daryl J Hoban James A Karlowsky Doripenem; Meropenem; Mutant prevention; P aeruginosa - BACKGROUND: With a limited number of available antimicrobial agents to treat Pseudomonas aeruginosa

Caulobacter Species as a Cause of Postneurosurgical Bacterial Meningitis in a Pediatric Patient

Kim Nichol MSc 0 James A Karlowsky 0 0 N Bridger, A Walkty, M Crockett, S Fanella, K Nichol, JA Karlowsky. Caulobacter species as a cause of postneurosurgical bacterial meningitis in a pediatric patient

Antimicrobial-Resistant Streptococcus pneumoniae in Canadian Hospitals: Results from the 2007 CANWARD Study

Antimicrobial-resistant Streptococcus pneumoniae in Canadian hospitals: Results from the 2007 CANWARD study Aleksandra K Wierzbowski MSc 0 Franil Tailor 0 Kim Nichol MSc 0 James A Karlowsky 0 Daryl

Mechanisms of Reduced Susceptibility to Ciprofloxacin in Escherichia coli Isolates from Canadian Hospitals

Can J Infect Dis Med Microbiol Mechanisms of reduced susceptibility to ciprofloxacin in Escherichia coli isolates from Canadian hospitals Patricia J Baudry-Simner 0 Amanpreet Singh 0 James A

Antimicrobial-Resistant Streptococcus pneumoniae in Canadian Hospitals: Results from the 2007 CANWARD Study

Antimicrobial-resistant Streptococcus pneumoniae in Canadian hospitals: Results from the 2007 CANWARD study Aleksandra K Wierzbowski MSc 0 Franil Tailor 0 Kim Nichol MSc 0 James A Karlowsky 0 Daryl

The New Fluoroquinolones: A Critical Review

OBJECTIVE: This paper reviews the literature available on the new fluoroquinolones – clinafloxacin, gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, sparfloxacin and trovafloxacin – to compare these agents with each other and contrast them with ciprofloxacin, an older fluoroquinolone.

The New Fluoroquinolones: A Critical Review

OBJECTIVE: This paper reviews the literature available on the new fluoroquinolones – clinafloxacin, gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, sparfloxacin and trovafloxacin – to compare these agents with each other and contrast them with ciprofloxacin, an older fluoroquinolone.

Antimicrobial-Resistant Streptococcus pneumoniae in Canadian Hospitals: Results from the 2007 CANWARD Study

Antimicrobial-resistant Streptococcus pneumoniae in Canadian hospitals: Results from the 2007 CANWARD study Aleksandra K Wierzbowski MSc 0 Franil Tailor 0 Kim Nichol MSc 0 James A Karlowsky 0 Daryl